Keisuke Yamamoto

List of Publications by Year
in descending order

65	3,205	147801	155660
papers	citations	31 h-index	55 g-index

66	66	66	5249
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature, 2020, 581, 100-105.	27.8	628
2	Loss of 5â€hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Science, 2012, 103, 670-676.	3.9	241
3	Slow Pull Versus Suction in Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Pancreatic Solid Masses. Digestive Diseases and Sciences, 2014, 59, 1578-1585.	2.3	152
4	Inhibition of reninâ€“angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. British Journal of Cancer, 2010, 103, 1644-1648.	6.4	150
5	Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. Cell, 2020, 183, 1202-1218.e25.	28.9	128
6	Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer. Cancer Discovery, 2020, 10, 1018-1037.	9.4	104
7	Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPÎ±. Carcinogenesis, 2014, 35, 2404-2414.	2.8	83
8	A large volume of visceral adipose tissue leads to severe acute pancreatitis. Journal of Gastroenterology, 2011, 46, 1213-1218.	5.1	79
9	Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Investigational New Drugs, 2012, 30, 708-713.	2.6	72
10	Endoscopic evaluation of factors contributing to intrapancreatic biliary stricture in autoimmune pancreatitis. Gastrointestinal Endoscopy, 2010, 71, 85-90.	1.0	69
11	Metallic stent with high axial force as a risk factor for cholecystitis in distal malignant biliary obstruction. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1557-1562.	2.8	65
12	Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Oncotarget, 2016, 7, 61469-61484.	1.8	64
13	Newly designed large cell Niti-S stent for malignant hilar biliary obstruction: a pilot study. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 463-467.	2.4	63
14	Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochemical and Biophysical Research Communications, 2010, 394, 1042-1046.	2.1	61
15	Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. Gut, 2011, 60, 1249-1253.	12.1	60
16	A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. Scientific Reports, 2016, 6, 23899.	3.3	60
17	Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. Journal of Hepatology, 2011, 55, 1400-1408.	3.7	57
18	Diagnostic utility of biopsy specimens for autoimmune pancreatitis. Journal of Gastroenterology, 2009, 44, 765-773.	5.1	53

#	Article	IF	Citations
19	Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer. Autophagy, 2020, 16, 1524-1525.	9.1	49
20	Autophagy is required for proper cysteine homeostasis in pancreatic cancer through regulation of SLC7A11. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	48
21	Erlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals. Cancer Research, 2013, 73, 2221-2234.	0.9	47
22	A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Investigational New Drugs, 2013, 31, 1294-1299.	2.6	45
23	Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer. Cell Metabolism, 2021, 33, 199-210.e8.	16.2	42
24	Bezafibrate for the treatment of primary sclerosing cholangitis. Journal of Gastroenterology, 2010, 45, 758-762.	5.1	41
25	Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Journal of Gastroenterology, 2013, 48, 238-246.	5.1	40
26	Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells. Carcinogenesis, 2013, 34, 2380-2388.	2.8	40
27	Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation. Oncogene, 2017, 36, 6262-6271.	5.9	38
28	Fever-based antibiotic therapy for acute cholangitis following successful endoscopic biliary drainage. Journal of Gastroenterology, 2011, 46, 1411-1417.	5.1	36
29	Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: <scp>GECA</scp>1. Cancer Science, 2012, 103, 1489-1492.	3.9	36
30	Quantitation of circulating satellite RNAs in pancreatic cancer patients. JCI Insight, 2016, 1, e86646.	5.0	34
31	Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Investigational New Drugs, 2011, 29, 1488-1493.	2.6	33
32	Risk for Mortality From Causes Other Than Pancreatic Cancer in Patients With Intraductal Papillary Mucinous Neoplasm of the Pancreas. Pancreas, 2013, 42, 687-691.	1.1	33
33	A Novel, Fully Covered Laser-Cut Nitinol Stent with Antimigration Properties for Nonresectable Distal Malignant Biliary Obstruction: A Multicenter Feasibility Study. Gut and Liver, 2013, 7, 725-730.	2.9	33
34	A Pilot Study for Combination Chemotherapy Using Gemcitabine and S-1 for Advanced Pancreatic Cancer. Oncology, 2009, 77, 300-303.	1.9	28
35	Impact of S-1 on the Survival of Patients With Advanced Pancreatic Cancer. Pancreas, 2010, 39, 989-993.	1.1	27
36	Sharpin promotes hepatocellular carcinoma progression via transactivation of Versican expression. Oncogenesis, 2016, 5, e277-e277.	4.9	27

#	Article	IF	Citations
37	Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Cancer Chemotherapy and Pharmacology, 2011, 67, 847-853.	2.3	26
38	The polar oxy-metabolome reveals the 4-hydroxymandelate CoQ10 synthesis pathway. Nature, 2021, 597, 420-425.	27.8	22
39	Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World Journal of Clinical Oncology, 2011, 2, 158.	2.3	22
40	The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Journal of Cancer Research and Clinical Oncology, 2015, 141, 933-939.	2.5	21
41	Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Pancreatology, 2013, 13, 285-289.	1.1	20
42	Inhibition of histone methyltransferase G9a attenuates liver cancer initiation by sensitizing DNA-damaged hepatocytes to p53-induced apoptosis. Cell Death and Disease, 2021, 12, 99.	6.3	19
43	Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation. Scientific Reports, 2019, 9, 18859.	3.3	18
44	Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the <scp>BET</scp> inhibitor <scp>JQ</scp>1. Cancer Science, 2018, 109, 3602-3610.	3.9	17
45	Gemcitabine and Oxaliplatin Combination Chemotherapy for Patients with Refractory Pancreatic Cancer. Oncology, 2011, 80, 97-101.	1.9	16
46	Clinical utility of singleâ€operator cholangiopancreatoscopy using a SpyGlass probe through an endoscopic retrograde cholangiopancreatography catheter. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1371-1376.	2.8	16
47	A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 1291-1297.	2.3	16
48	Disease-Specific Mortality Among Patients With Intraductal Papillary Mucinous Neoplasm of the Pancreas. Clinical Gastroenterology and Hepatology, 2014, 12, 486-491.	4.4	16
49	MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages. Gastroenterology, 2022, 162, 1272-1287.e16.	1.3	16
50	Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Scientific Reports, 2020, 10, 21194.	3.3	14
51	The results of the Tokyo Trial of Prevention of Post-ERCP Pancreatitis with Risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial. Journal of Gastroenterology, 2013, 48, 982-988.	5.1	13
52	NOTES and endoscopic pancreatic necrosectomy for the GI endoscopist. Journal of Hepato-Biliary-Pancreatic Surgery, 2009, 16, 270-273.	2.0	12
53	Targeting autophagy as a therapeutic strategy against pancreatic cancer. Journal of Gastroenterology, 2022, 57, 603-618.	5.1	12
54	Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis. Cancer Genomics and Proteomics, 2020, 17, 695-705.	2.0	9

#	Article	IF	Citations
55	5-Aminolevulinic acid-mediated photodynamic activity in patient-derived cholangiocarcinoma organoids. Surgical Oncology, 2020, 35, 484-490.	1.6	8
56	A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 911-915.	2.3	7
57	Noncalcified pancreatic stone treated with electrohydraulic lithotripsy using SpyGlass pancreatoscopy. Endoscopy, 2011, 43, E272-E272.	1.8	5
58	ENDOSCOPIC REMOVAL OF A SPONTANEOUSLY FRACTURED BILIARY UNCOVERED SELF-EXPANDABLE METAL STENT. Digestive Endoscopy, 2012, 24, 182-184.	2.3	5
59	No Survival Benefit from the Inhibition of Reninâ€“Angiotensin System in Biliary Tract Cancer. Anticancer Research, 2016, 36, 4965-4970.	1.1	5
60	Survey on Preclinical Methods to Assess Collateral Thermal Damage to Tissues Caused by Surgical Devices. Journal of Japan Society of Computer Aided Surgery, 2017, 19, 63-73.	0.0	0
61	Transluminal endoscopic necrosectomy for infected pancreatic necrosis. Progress of Digestive Endoscopy, 2009, 75, 116-117.	0.0	0
62	A phase 1 trial of GSL (gemcitabine, S-1, LV) combination therapy in advanced pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 290-290.	1.6	0
63	Associations between K-ras mutation, smoking, and prognosis of pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 298-298.	1.6	0
64	Epigenome modifying enzymes regulate development and progression of pancreatic cancers. Suizo, 2016, 31, 69-75.	0.1	0
65	Abstract PO-067: A multi-omics study in patient-derived organoids reveals MNX1-HNF1B axis to be indispensable for intraductal mucinous papillary neoplasm lineages. , 2021, , .		0